company background image
LBT

LBT InnovationsASX:LBT Stock Report

Market Cap

AU$33.2m

7D

4.5%

1Y

-8.0%

Updated

20 Oct, 2021

Data

Company Financials
LBT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

LBT Overview

LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia and Switzerland.

Price History & Performance

Summary of all time highs, changes and price drops for LBT Innovations
Historical stock prices
Current Share PriceAU$0.12
52 Week HighAU$0.071
52 Week LowAU$0.17
Beta-0.11
1 Month Change-17.86%
3 Month Change9.52%
1 Year Change-8.00%
3 Year Change4.55%
5 Year Change-77.45%
Change since IPO-41.03%

Recent News & Updates

Sep 15
Is LBT Innovations (ASX:LBT) Using Debt In A Risky Way?

Is LBT Innovations (ASX:LBT) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

May 04
Is LBT Innovations (ASX:LBT) Using Too Much Debt?

Is LBT Innovations (ASX:LBT) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Jan 04
How Much Is LBT Innovations Limited (ASX:LBT) Paying Its CEO?

How Much Is LBT Innovations Limited (ASX:LBT) Paying Its CEO?

Brent Barnes became the CEO of LBT Innovations Limited ( ASX:LBT ) in 2016, and we think it's a good time to look at...

Shareholder Returns

LBTAU Medical EquipmentAU Market
7D4.5%3.0%1.7%
1Y-8.0%-6.5%20.2%

Return vs Industry: LBT underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.

Return vs Market: LBT underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is LBT's price volatile compared to industry and market?
LBT volatility
LBT Beta-0.11
Industry Beta0.57
Market Beta1

Stable Share Price: LBT is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: LBT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2004n/aBrent Barneshttps://www.lbtinnovations.com

LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia and Switzerland. The company offers MicroStreak, an automated culture-plate streaking and inoculation system; and Automated Plate Assessment System, a platform technology that automates culture-plate screening and interpretation. It also develops Automated Gram Strain Assessment for the automated interpretation of gram stain image analysis; WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds; and devices that can detect biofilms in the presence of mammalian tissue.

LBT Innovations Fundamentals Summary

How do LBT Innovations's earnings and revenue compare to its market cap?
LBT fundamental statistics
Market CapAU$33.25m
Earnings (TTM)-AU$7.26m
Revenue (TTM)AU$35.00k

958.3x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LBT income statement (TTM)
RevenueAU$35.00k
Cost of RevenueAU$0
Gross ProfitAU$35.00k
ExpensesAU$7.30m
Earnings-AU$7.26m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.025
Gross Margin100.00%
Net Profit Margin-20,742.86%
Debt/Equity Ratio11.8%

How did LBT perform over the long term?

See historical performance and comparison

Valuation

Is LBT Innovations undervalued compared to its fair value and its price relative to the market?

1.34x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LBT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LBT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LBT is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: LBT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LBT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LBT is good value based on its PB Ratio (1.3x) compared to the AU Medical Equipment industry average (5x).


Future Growth

How is LBT Innovations forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LBT Innovations has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has LBT Innovations performed over the past 5 years?

-31.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LBT is currently unprofitable.

Growing Profit Margin: LBT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LBT is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.

Accelerating Growth: Unable to compare LBT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LBT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: LBT has a negative Return on Equity (-29.18%), as it is currently unprofitable.


Financial Health

How is LBT Innovations's financial position?


Financial Position Analysis

Short Term Liabilities: LBT's short term assets (A$11.6M) exceed its short term liabilities (A$2.6M).

Long Term Liabilities: LBT's short term assets (A$11.6M) exceed its long term liabilities (A$8.2M).


Debt to Equity History and Analysis

Debt Level: LBT's debt to equity ratio (11.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if LBT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LBT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LBT has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 26.6% each year.


Dividend

What is LBT Innovations's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LBT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LBT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Brent Barnes

5.17yrs

Tenure

AU$460,000

Compensation

Mr. Brenton John Barnes, also known as Brent, has been the Chief Executive Officer and Director of LBT Innovations Limited since August 08, 2016. Mr. Barnes has been the Managing Director of LBT Innovation...


CEO Compensation Analysis

Compensation vs Market: Brent's total compensation ($USD343.93K) is about average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Brent's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: LBT's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: LBT's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

LBT Innovations Limited's employee growth, exchange listings and data sources


Key Information

  • Name: LBT Innovations Limited
  • Ticker: LBT
  • Exchange: ASX
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$33.248m
  • Shares outstanding: 289.12m
  • Website: https://www.lbtinnovations.com

Location

  • LBT Innovations Limited
  • 16 Anster Street
  • Adelaide
  • South Australia
  • 5000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:25
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.